# Amer M. Zeidan

Source: https://onco.cc/people/amer-zeidan/  
OnCo record `amer-zeidan` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Yale haematologist who led VERONA, the trial that asked whether adding venetoclax to azacitidine helps people with higher-risk myelodysplastic syndromes, and found it did not lengthen survival.

## Summary

Amer Zeidan leads the myelodysplastic syndromes programme at Yale Cancer Center. He was the lead investigator of VERONA, the phase 3 trial of venetoclax plus azacitidine against azacitidine alone in newly diagnosed higher-risk MDS, and presented its results in 2024: the combination did not improve overall survival. He publishes widely on MDS treatment patterns, health outcomes and trial endpoints.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: mds; trialist
- Role: Haematologist, Yale Cancer Center
- Specialisms: Myelodysplastic syndromes; Acute myeloid leukaemia; Trial design and outcomes research

## Connected records

- cancers: [Higher-risk myelodysplastic syndromes](https://onco.cc/cancers/mds-higher-risk/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- institutions: [Yale Cancer Center / Smilow Cancer Hospital](https://onco.cc/institutions/yale-cancer-center/)
- trials: [VERONA](https://onco.cc/trials/verona/)
- key papers: [COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions](https://onco.cc/key-papers/paper-commands-luspatercept-mds-lancet-2023/), [Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes](https://onco.cc/key-papers/paper-amer-zeidan-n-engl-j-med-2020/), [Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia](https://onco.cc/key-papers/paper-amer-zeidan-j-clin-oncol-2021/)

---
JSON: https://onco.cc/api/v1/entities/amer-zeidan.json